XTX Markets’s Catalyst Pharmaceutical CPRX Stock Holding History

XTX Markets’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-18,749	Closed	-$56K	–	206
2020 Q3	$56K	Buy	+18,749	New	+$73.3K	0.27%	84

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

XTX Markets's CPRX Position: Q4 2020 in Review

XTX Markets sold out of Catalyst Pharmaceutical (CPRX) in Q4 2020, closing a stake of 18,749 shares — an estimated $56K sold.

XTX Markets first reported a position in CPRX in Q3 2020 and held it in 1 quarter. The position peaked at $56K in Q3 2020. 135 funds tracked by Wall St. Rank hold CPRX as of Q4 2020.

XTX Markets reported no remaining Catalyst Pharmaceutical position as of Q4 2020 after selling out during the quarter.
XTX Markets sold 18,749 Catalyst Pharmaceutical shares in Q4 2020, an estimated $56K.
XTX Markets first reported a position in Catalyst Pharmaceutical in Q3 2020 and held it in 1 quarter.
XTX Markets's Catalyst Pharmaceutical position peaked at $56K in Q3 2020.
135 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.